Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jiaoti Huang, M.D., Ph.D.
Jiaoti Huang, M.D., Ph.D.

Specialty:

Pathology

General Information:

Gender:
Male
Language(s):
English, Chinese

Affiliation(s):

Professor and Director of Urologic Pathology, Department of Pathology and Laboratory Medicine
Co-Director, Pathway Pathology Laboratory, Institute for Molecular Medicine
Member, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Anatomic and Clinical Pathology, Memorial Sloan-Kettering Cancer Center, 1999 - 2000
Residency:
Anatomic and Clinical Pathology, New York University School of Medicine, 1995 - 1999
Medical Degree:
M.D., Anhui Medical University, 1983
Degree:
Ph.D., New York University School of Medicine, 1991

Certification(s):

Board Certification(s):
Anatomic Pathology and Clinical Pathology, American Board of Pathology, 2000

Practice Information:

Clinical Interest(s):
Tumors of prostate, bladder, kidney and testis

Scientific Interest(s):

Dr. Jiaoti Huang’s laboratory has been studying the molecular mechanisms by which prostate cancer becomes insensitive to hormonal therapy and progresses to castration resistant tumors. His lab is actively engaged in drug discovery and in developing tumor models that can be used for the development of tools used in diagnosis, imaging, prevention and therapy of prostate cancer.

Selected Cancer-Related Publications:

Ding B, Sun Y, Huang J. Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem. 2012 Apr 27;287(18):14621-30. Epub 2012 Mar 12

Chen H, Sun Y, Wu C, Magyar C, Li X, Cheng L, Yao JL, Shen S, Osunkoya AO, Liang C, Huang J, Magyar CE. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 2012 Jun;19(3):321-31.

Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C, Huang J. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012 Jun;11(6):1320-31. Epub 2012 Apr 5

Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011 Nov;71(15):1668-79. Epub 2011 Mar 22

Huang J, Witte ON. A seminal finding for prostate cancer? N Engl J Med. 2010 Jan 14;362(2):175-6.